Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$5.20 USD
+0.02 (0.39%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $5.19 -0.01 (-0.19%) 7:22 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Brokerage Reports
Corvus Pharmaceuticals, Inc. [CRVS]
Reports for Purchase
Showing records 1 - 20 ( 154 total )
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
R&D Symposium Highlights Diversified Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Evaluating Mupadolimab as Front-Line Treatment of NSCLC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Catalysts from Our Coverage Universe: YE2021 and Beyond
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
CD73 Inhibition Associated with Tumor Regression in SITC Poster
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eyes on Mupadolimab Update at SITC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Recent COVID-19 Publication, but Lateral Competitor Driving Stock
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q21: Update on Clinical Progress and Financials
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Mupadolimab to Target Virus Associated Cancers; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Cuts COVID-19 Trial to Wisely Focus on Core Oncology Programs
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Re-Prioritizing Mupadolimab Development to Oncology; Lower PT to $6; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S